BioCryst Pharmaceuticals financials
$8.27−2.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.3M | $156.4M | $406.6M | $159.4M | $163.4M | $145.5M | $131.5M | $117.1M | $109.3M | $92.8M | $93.4M | $86.7M |
| Gross profit | $214.4M | $151.0M | $397.0M | $157.2M | $160.6M | $141.0M | $125.4M | $113.9M | $107.6M | $91.5M | $91.8M | $85.6M |
| Gross margin | 98.2% | 96.6% | 97.7% | 98.6% | 98.3% | 96.9% | 95.4% | 97.3% | 98.4% | 98.6% | 98.3% | 98.7% |
| Operating income | $98.5M | -$701.6M | $260.4M | $29.6M | $29.8M | $21.2M | -$4.5M | $7.7M | $8.8M | -$14.5M | -$42.7M | -$11.9M |
| Net income | $78.4M | -$721.8M | $245.8M | $12.9M | $5.1M | $32.0K | -$26.8M | -$14.0M | -$12.7M | -$35.4M | -$61.7M | -$36.1M |
| Net margin | 35.9% | −461.5% | 60.5% | 8.1% | 3.1% | 0.0% | −20.4% | −12.0% | −11.6% | −38.1% | −66.1% | −41.7% |
| Diluted EPS | $0.30 | $-2.98 | $1.12 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 |
| EBITDA | $98.4M | -$700.5M | $260.8M | $29.9M | $30.1M | $21.6M | -$4.2M | $8.0M | $9.1M | -$14.2M | -$42.7M | -$11.5M |
| Operating cash flow | $104.3M | -$61.8M | $292.0M | $41.6M | $41.3M | -$27.5M | -$5.2M | $8.2M | -$1.4M | -$53.7M | -$8.9M | -$19.9M |
| Free cash flow | $104.1M | -$62.2M | $291.2M | $40.3M | $41.1M | -$27.7M | -$5.9M | $8.2M | -$1.5M | -$53.9M | -$9.5M | -$20.9M |
| Diluted shares | 265.2M | 242.3M | 219.3M | 219.9M | 219.9M | 215.3M | 207.4M | 206.9M | 206.4M | 206.1M | 201.5M | 189.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.0M | $171.6M | $89.7M | $84.1M | $88.0M | $105.2M |
| Short-term investments | $197.6M | $66.8M | $185.0M | $128.8M | $172.0M | $189.9M |
| Total debt | $824.1M | $845.1M | $468.4M | $674.3M | $730.0M | $820.4M |
| Total assets | $557.9M | $465.1M | $514.2M | $446.4M | $457.2M | $480.0M |
| Total liabilities | $1.01B | $1.02B | $633.3M | $834.3M | $878.8M | $932.0M |
| Shareholders' equity | -$454.3M | -$553.8M | -$119.2M | -$387.9M | -$421.6M | -$451.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology